Karo Pharma AB (publ) (KARBF) Research

Headquartered in Stockholm, Sweden, Karo Pharma AB (publ) specializes in the development and commercialization of both prescription pharmaceuticals and over-the-counter (OTC) health products. These offerings reach pharmacies and retail sectors across numerous global markets, including its home country of Sweden, the Nordic region (Norway, Denmark, Finland), major European economies (France, Germany, Italy), the wider European continent, the United States, and approximately 90 other countries worldwide. The European and Nordic markets represent a particularly strong focus for the company. Karo Pharma boasts a diverse portfolio spanning several health categories. For skin health, prominent brands include Remescar, Locobase, Decubal, and indy beauty. Its intimate health segment features Pevaryl, Multi Gyn, Asan, and Selexid, while foot care is addressed through brands such as Pevaryl, CCS, Nailner, and wortie. The company also provides relief for pain, coughs, and colds under brand names like Paracet, Ibux, Mollipect, and Viruseptin. Essential prescription drugs are marketed under the Burinex, Centyl, Kaleorid, and Lithionit labels. Furthermore, a range of wellness products is available through brands including nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare. Distribution of these products is managed through various channels, encompassing direct sales organizations, extensive networks of distributors, and online platforms. The company, initially incorporated in 1987, was formerly named Karo Bio AB (publ) before officially rebranding to Karo Pharma AB (publ) in March 2016.

Open Karo Pharma AB (publ) (KARBF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.